CROSSJECT |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.31 EUR | -2.74% |
|
+16.31% | -53.52% |
| May. 27 | Crossject: capital increase until May 30 | CF |
| May. 03 | Crossject: praised for extended agreement on Zepizure | CF |
Business Summary
Number of employees: 105
Sales per Business
| EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
|---|---|---|---|---|---|
Needle-free Injection System
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | +4.61% |
Sales per region
| EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
|---|---|---|---|---|---|
France
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | +4.61% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 01-08-07 | |
Olivier Giré
PRN | Corporate Officer/Principal | - | 15-12-31 |
| General Counsel | - | 12-12-31 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Daniel Teper
BRD | Director/Board Member | 64 | 23-06-06 |
Eric Nemeth
BRD | Director/Board Member | 65 | - |
Philippe Monnot
CHM | Chairman | 65 | - |
Yannick Plétan
BRD | Director/Board Member | - | - |
| Director/Board Member | - | - |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 37,086,773 | 27,061,430 ( 72.97 %) | 0 | 72.97 % |
| Stock B | 0 | 1,655,925 | 0 | 0 |
Holdings
| Name | Equities | % | Valuation |
|---|---|---|---|
CROSSJECT 0.29% | 106,603 | 0.29% | 233,670 $ |
Company contact information
Sector
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.31
EUR
Average target price
5
EUR
Spread / Average Target
+116.45%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -53.52% | 95.93M | |
| +16.58% | 255M |
- Stock Market
- Equities
- ALCJ Stock
- Company Crossject
